Stereotactic body radiotherapy and hormone treatment resulted in 40.1% 12-month progression-free survival in a recent study. Administration of radiotherapy in conjunction with hormone treatment has ...

Adding PSMA-based radioligand therapy to metastasis-directed SBRT in men with oligorecurrent prostate cancer delays progression, defined by PSMA PET/CT. As PSMA-targeting RLT improves survival ...

SBRT and surgery showed similar overall survival in stage I NSCLC, offering a non-invasive option for high-risk surgical patients. Surgery demonstrated better disease-free and recurrence-free survival ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

This prospective study included 135 patients (median age, 67 years; 66 women) who underwent MRI-guided SBRT for liver metastases across seven international centres between April 2019 and April 2023.

Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

SBRT involves constructing very compact high-dose volumes in and about the tumor. Tumor position must be accurately assessed throughout treatment, especially for tumors that move with respiration.

CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma. CURE recently spoke with Dr. Laura Dawson, a professor and chair of the ...

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim ...